Luye Pharma Group Ltd.
PharmaNanjing, Jiangsu, China · Est. 2002
Luye Pharma Group Ltd. is a Chinese pharmaceutical company focused on researching, developing, and commercializing innovative pharmaceutical products across multiple therapeutic areas.
3
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
7
Indications↗
Distinct diseases across all programs
75
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
Pipeline Snapshot
By Phase
3 drugs in development
Approved1
Phase 31
Phase 22
Preclinical1
By Therapeutic Area
top 4
Respiratory
120%
Psychiatry
120%
Musculoskeletal
120%
Oncology
120%
R&D Momentum
55/100
Pipeline Velocity
25/100
Trial Completion Rate
100/100
Pipeline Concentration
20/100
Pipeline Freshness
64/100
Strategic Signals
- ↗Active in Respiratory but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Earlier
Jun 27, 2026TrialAn Open-Label, Single-Dose, Parallel-Group Study to Evaluate the Pharmacokinetics, Safety and Tolerability of LY03015 in Healthy Chinese and Caucasian Adult Subjects
Mar 31, 2026TrialLPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation
Mar 31, 2026TrialA Phase 2 Study to Evaluate the Efficacy and Safety of LY03020 in Acutely Psychotic Participants With Schizophrenia
Oct 28, 2025TrialTo Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Food Effects of LY03021 in Healthy Chinese Subjects
Aug 20, 2025TrialA Phase 1 MAD Study to Evaluate the Safety and Tolerability of LY03020
Jul 30, 2025TrialA Food Effect Study of LY03020 in Healthy Subjects
May 1, 2025TrialA Phase 1, MAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LY03017
4 more events
Feb 1, 2025TrialEffect of Food and Age on the Pharmacokinetics of LY03017
Jan 14, 2025TrialSafety and Efficacy of LPM3770164 Sustained-release Tablets in Patients With Tardive Dyskinesia
Oct 9, 2024TrialIdentify Effective Doses of LY01021 in Controlled Ovarian Hyperstimulation (COH) for Female Subjects Undergoing Assisted Reproductive Technology (ART)
Sep 14, 2024TrialLurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC
Details
Company Info
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Therapeutic Focus
OncologyCardiovascularCentral Nervous System
Pipeline
Drug Pipeline
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Musculoskeletal
Psychiatry
Respiratory
Unknown / Other
Musculoskeletal
Oncology
Psychiatry
Schizophrenia
LY03020Phase 2
Respiratory
Unknown / Other
Cesarean Section
Morphine hydrochloridePreclinical
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)